Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMB-001 in Participants With Glanzmann Thrombasthenia
NCT06211634Phase 2Active, not recruiting
- Sponsor
- Hemab Therapeutics
- Start
- Dec 2022
- Primary completion
- Aug 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of sutacimig in Glanzmann thrombasthenia (GT), sponsored by Hemab Therapeutics. Started Dec 2022; status: active, not recruiting.
02
Drugs
sutacimig
03
Conditions
Glanzmann thrombasthenia (GT)
Beyond the preview
Go deeper on NCT06211634.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06211634.